Your browser doesn't support javascript.
loading
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci, O; Sahin, U; Schulze-Bergkamen, H; Zvirbule, Z; Lordick, F; Koeberle, D; Thuss-Patience, P; Ettrich, T; Arnold, D; Bassermann, F; Al-Batran, S E; Wiechen, K; Dhaene, K; Maurus, D; Gold, M; Huber, C; Krivoshik, A; Arozullah, A; Park, J W; Schuler, M.
Afiliación
  • Türeci O; Ci3 - Cluster of Individualized Immune Intervention, Mainz. Electronic address: tureci@uni-mainz.de.
  • Sahin U; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz.
  • Schulze-Bergkamen H; National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Zvirbule Z; Riga East University Hospital, LLC, Riga, Latvia.
  • Lordick F; University Cancer Center Leipzig, University Medicine Leipzig, Leipzig, Germany.
  • Koeberle D; Department of Oncology and Hematology, Kantonsspital, St. Gallen, Switzerland.
  • Thuss-Patience P; Charite University Medicine Berlin, Medical Clinic of Hematology, Oncology and Tumor Immunology, Berlin.
  • Ettrich T; Department of Internal Medicine I, Ulm University Hospital, Ulm.
  • Arnold D; Asklepios Tumorzentrum Hamburg, AK Altona, Hamburg.
  • Bassermann F; Klinikum rechts der Isar, Technische Universität München, Munich.
  • Al-Batran SE; Nordwest Hospital, Institute of Clinical Cancer Research, University Cancer Center, Frankfurt.
  • Wiechen K; Klinikum Worms gGmbH, Institute for Pathology, Worms, Germany.
  • Dhaene K; MD Dhaene Pathology Lab BVBA, Destelbergen, Belgium.
  • Maurus D; Formerly of Ganymed GmbH (AG), Mainz, Germany.
  • Gold M; Formerly of Ganymed GmbH (AG), Mainz, Germany.
  • Huber C; Ci3 - Cluster of Individualized Immune Intervention, Mainz; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz.
  • Krivoshik A; Astellas Pharma, Inc., Northbrook, USA.
  • Arozullah A; Astellas Pharma, Inc., Northbrook, USA.
  • Park JW; Astellas Pharma, Inc., Northbrook, USA.
  • Schuler M; West German Cancer Center, University Duisburg-Essen, Essen; German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.
Ann Oncol ; 30(9): 1487-1495, 2019 09 01.
Article en En | MEDLINE | ID: mdl-31240302
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido